X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which is being evaluated in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lead Product(s): ICP-248,Orelabrutinib
Therapeutic Area: Oncology Product Name: ICP-248
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
ICP-723 (zurletrectinib) is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC. It is under phase 1 trials for pediatric patients with age 2 to 12 years old with advanced or metastatic solid tumors, breast cancer & colorectal cancer.
Lead Product(s): Zurletrectinib
Therapeutic Area: Oncology Product Name: ICP-723
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
Minjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting immunotherapy, which is approved in combination with lenalidomide has been approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: Minjuvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2024
Details:
ICP-248 is a novel, orally bioavailable, small molecule drug which is BCL2-selective inhibitor. It is currently being evaluated in phase 1 clinical trials for the treatment of B cell malignancy.
Lead Product(s): ICP-248
Therapeutic Area: Oncology Product Name: ICP-248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
ICP-332 is a novel TYK2 (Tyrosine Kinase 2) inhibitor which is under phase 2 clinical development for the treatment of patients with moderate-to-severe atopic dermatitis (AD).
Lead Product(s): ICP-332
Therapeutic Area: Dermatology Product Name: ICP-332
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2023
Details:
Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for the treatment of primary immune thrombocytopenia (ITP) in China.
Lead Product(s): Orelabrutinib
Therapeutic Area: Immunology Product Name: Hibruka
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
ICP-723 (zurletrectinib) is a second generation pan-TRK inhibitor, which is investigated for the treatment of advanced or metastatic solid tumors harboring NTRK fusion genes, including breast cancer, colorectal cancer, lung cancer, thyroid cancer, sarcoma.
Lead Product(s): Zurletrectinib
Therapeutic Area: Oncology Product Name: ICP-723
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in advanced NSCLC.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arrivent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
